<p>Palisade Bio（纳斯达克代码：PALI - 获取免费报告）在周六发布的报告中被华尔街 Zen 的股票研究分析师将评级从 “持有” 下调至 “卖出”。</p>
<p>其他一些股票分析师也最近对该公司发表了评论。Weiss Ratings 在 1 月 22 日的报告中重申了对 Palisade Bio 股票的 “卖出（e+）” 评级。花旗集团在 11 月 11 日的研究报告中重申了对 Palisade Bio 股票的 “买入” 评级。Piper Sandler 在 12 月 29 日的研究报告中开始覆盖 Palisade Bio。他们对该股票给予了 “增持” 评级，并设定了 25.00 美元的目标价。Clear Str 在 12 月 29 日的研究报告中将 Palisade Bio 的股票评级提升至 “强力买入”。最后，B. Riley Financial 在 1 月 9 日的报告中对 Palisade Bio 股票进行了覆盖。他们给予了 “买入” 评级，并设定了 7.00 美元的目标价。一位研究分析师对该股票给予了 “强力买入” 评级，四位分析师给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 16.00 美元。</p>
<p><strong>获取我们对 Palisade Bio 的最新分析</strong></p>
<h2>Palisade Bio 股价上涨 9.3%</h2>
<p>纳斯达克 PALI 周五开盘价为 1.64 美元。该公司的市值为 2.4436 亿美元，市盈率为-0.77，贝塔值为 1.58。Palisade Bio 的 12 个月低点为 0.53 美元，12 个月高点为 2.64 美元。该股票的 50 日移动平均线为 1.90 美元，200 日移动平均线为 1.51 美元。</p>
<p>Palisade Bio（纳斯达克代码：PALI - 获取免费报告）最后一次发布财报是在 11 月 10 日。该公司报告的每股收益为（0.38 美元），低于分析师的共识预期（0.32 美元）0.06 美元。作为一个整体，卖方分析师预测 Palisade Bio 在当前财政年度将发布-12.43 的每股收益。</p>
<h2>对 Palisade Bio 的对冲基金看法</h2>
<p>一家机构投资者最近在 Palisade Bio 股票中购买了新头寸。根据该公司在最近向证券交易委员会提交的文件，Total Clarity Wealth Management Inc.在第四季度收购了 Palisade Bio, Inc.（纳斯达克代码：PALI - 免费报告）的新头寸。该基金收购了 29,935 股该公司的股票，价值约 70,000 美元。机构投资者持有该公司 11.79% 的股票。</p>
<h2>Palisade Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Palisade Bio, Inc 是一家临床阶段的生物技术公司，专注于开创局部免疫疗法以治疗癌症和炎症性疾病。该公司利用一种专有的前药平台，旨在在肿瘤微环境或炎症部位选择性激活治疗药物。其核心战略集中在通过刺激先天免疫系统，利用 Toll 样受体 9（TLR9）激动剂来驱动靶向免疫反应，同时最小化全身暴露和毒性。</p>
<p>该公司的主要产品候选药物 PDS0108 是一种肿瘤内 TLR9 激动剂前药，目前正在进行针对晚期实体肿瘤患者的 1/2 期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Palisade Bio 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFMSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFMSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Palisade Bio 吗？</h2>
<p>在你考虑 Palisade Bio 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Palisade Bio 并不在名单上。</p>
<p>虽然 Palisade Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PALI

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>华尔街禅将 Palisade Bio (NASDAQ:PALI) 的评级从 “持有” 下调至 “卖出”。其他分析师的观点不一，Weiss Ratings 维持 “卖出 (e+)” 评级，而花旗集团则给予 “买入” 评级。该股票的平均评级为 “适度买入”，目标价格为 16.00 美元。Palisade Bio 的市值为 2.4436 亿美元，报告每股收益亏损为（0.38）美元，未能达到预期。该公司专注于针对癌症和炎症性疾病的局部免疫疗法，其主要产品正在进行临床试验</p>

<p>Palisade Bio (NASDAQ:PALI - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report released on Saturday.</p>
<div class="lb-trans"><p>Palisade Bio（纳斯达克代码：PALI - 获取免费报告）在周六发布的报告中被华尔街 Zen 的股票研究分析师将评级从 “持有” 下调至 “卖出”。</p>
</div><p>A number of other equities analysts have also recently commented on the company. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Palisade Bio in a report on Thursday, January 22nd. Citigroup reiterated a &#34;buy&#34; rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Piper Sandler began coverage on Palisade Bio in a research note on Monday, December 29th. They issued an &#34;overweight&#34; rating and a $25.00 price target on the stock. Clear Str raised shares of Palisade Bio to a &#34;strong-buy&#34; rating in a research report on Monday, December 29th. Finally, B. Riley Financial initiated coverage on shares of Palisade Bio in a report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average target price of $16.00.</p>
<div class="lb-trans"><p>其他一些股票分析师也最近对该公司发表了评论。Weiss Ratings 在 1 月 22 日的报告中重申了对 Palisade Bio 股票的 “卖出（e+）” 评级。花旗集团在 11 月 11 日的研究报告中重申了对 Palisade Bio 股票的 “买入” 评级。Piper Sandler 在 12 月 29 日的研究报告中开始覆盖 Palisade Bio。他们对该股票给予了 “增持” 评级，并设定了 25.00 美元的目标价。Clear Str 在 12 月 29 日的研究报告中将 Palisade Bio 的股票评级提升至 “强力买入”。最后，B. Riley Financial 在 1 月 9 日的报告中对 Palisade Bio 股票进行了覆盖。他们给予了 “买入” 评级，并设定了 7.00 美元的目标价。一位研究分析师对该股票给予了 “强力买入” 评级，四位分析师给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 16.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Palisade Bio</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Palisade Bio 的最新分析</strong></p>
</div><h2>Palisade Bio Trading Up 9.3%</h2>
<div class="lb-trans"><h2>Palisade Bio 股价上涨 9.3%</h2>
</div><p>NASDAQ PALI opened at $1.64 on Friday. The company has a market cap of $244.36 million, a PE ratio of -0.77 and a beta of 1.58. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The stock has a 50 day moving average of $1.90 and a 200-day moving average of $1.51.</p>
<div class="lb-trans"><p>纳斯达克 PALI 周五开盘价为 1.64 美元。该公司的市值为 2.4436 亿美元，市盈率为-0.77，贝塔值为 1.58。Palisade Bio 的 12 个月低点为 0.53 美元，12 个月高点为 2.64 美元。该股票的 50 日移动平均线为 1.90 美元，200 日移动平均线为 1.51 美元。</p>
</div><p>Palisade Bio (NASDAQ:PALI - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.06). As a group, sell-side analysts predict that Palisade Bio will post -12.43 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Palisade Bio（纳斯达克代码：PALI - 获取免费报告）最后一次发布财报是在 11 月 10 日。该公司报告的每股收益为（0.38 美元），低于分析师的共识预期（0.32 美元）0.06 美元。作为一个整体，卖方分析师预测 Palisade Bio 在当前财政年度将发布-12.43 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Palisade Bio</h2>
<div class="lb-trans"><h2>对 Palisade Bio 的对冲基金看法</h2>
</div><p>An institutional investor recently bought a new position in Palisade Bio stock. Total Clarity Wealth Management Inc. acquired a new position in Palisade Bio, Inc. (NASDAQ:PALI - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 29,935 shares of the company's stock, valued at approximately $70,000. Institutional investors own 11.79% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Palisade Bio 股票中购买了新头寸。根据该公司在最近向证券交易委员会提交的文件，Total Clarity Wealth Management Inc.在第四季度收购了 Palisade Bio, Inc.（纳斯达克代码：PALI - 免费报告）的新头寸。该基金收购了 29,935 股该公司的股票，价值约 70,000 美元。机构投资者持有该公司 11.79% 的股票。</p>
</div><h2>Palisade Bio Company Profile</h2>
<div class="lb-trans"><h2>Palisade Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.</p>
<div class="lb-trans"><p>Palisade Bio, Inc 是一家临床阶段的生物技术公司，专注于开创局部免疫疗法以治疗癌症和炎症性疾病。该公司利用一种专有的前药平台，旨在在肿瘤微环境或炎症部位选择性激活治疗药物。其核心战略集中在通过刺激先天免疫系统，利用 Toll 样受体 9（TLR9）激动剂来驱动靶向免疫反应，同时最小化全身暴露和毒性。</p>
</div><p>The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 PDS0108 是一种肿瘤内 TLR9 激动剂前药，目前正在进行针对晚期实体肿瘤患者的 1/2 期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Palisade Bio</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Palisade Bio 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFMSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PALI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Palisade Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Palisade Bio 吗？</h2>
</div><p>Before you consider Palisade Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Palisade Bio 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Palisade Bio 并不在名单上。</p>
</div><p>While Palisade Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Palisade Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen

Market Beat

Palisade Bio

Palisade Bio（纳斯达克股票代码：PALI）被华尔街 Zen 下调至卖出评级